Scabies Clinical Trial
— EAHSPOfficial title:
East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities
The purpose of this study is to determine whether a coordinated regional approach to healthy
skin programs in six remote Aboriginal communities can demonstrate, not only a reduction in
the burden of scabies and streptococcal skin sores, but also broad health benefits,
including primary prevention of some chronic diseases that occur at particularly high rates
in Australian Aboriginal communities.
The primary objectives of the Program are:
- Demonstrate a reduction in scabies and skin sores on a regional basis
- Demonstrate the broader public health effects of Healthy Skin Programs, particularly
those relating to chronic diseases such as rheumatic fever and renal diseases
- Build on the existing Indigenous capacity by assisting in the development of new
knowledge and skills to improve the health and well being of Indigenous communities
- Establish the feasibility of incorporating Healthy Skin Programs into existing health
service delivery
Status | Completed |
Enrollment | 2329 |
Est. completion date | August 2007 |
Est. primary completion date | August 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 15 Years |
Eligibility |
Inclusion Criteria: - All children aged <15 years in the participating communities Exclusion Criteria: |
Observational Model: Ecologic or Community, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Australia | Menzies School of Health Research | Casuarina | Northern Territory |
Lead Sponsor | Collaborator |
---|---|
Menzies School of Health Research | Cooperative Research Centre for Aboriginal Health, Murdoch Childrens Research Institute, University of Melbourne |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduced prevalence of scabies among children in the participating communities from 30% (expected prevalence pre-program) to <10% at least 2 years following the introduction of the program | 2 years | No | |
Primary | Reduced prevalence of skin sores among children in the participating communities from 50% (expected prevalence pre-program) to <25% at least 2 years following the introduction of the program | 2 years | No | |
Secondary | Reduced severity of skin sores among children in the participating communities from 40% classified as moderate/severe (expected pre-program) to <15% classified as moderate/severe at least two years following the introduction of the program | 2 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02572986 -
A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies
|
Phase 3 | |
Completed |
NCT05025696 -
Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies
|
N/A | |
Completed |
NCT04205669 -
Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon
|
Phase 4 | |
Completed |
NCT02254564 -
PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
|
||
Not yet recruiting |
NCT06404333 -
Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)
|
Phase 2 | |
Completed |
NCT03676140 -
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 3 | |
Recruiting |
NCT05875441 -
Efficacy and Safety Study of Moxidectin in Adults With Scabies
|
Phase 2 | |
Completed |
NCT02978508 -
Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
|
Phase 3 | |
Recruiting |
NCT04332068 -
Ivermectin Safety in Small Children
|
Phase 2 | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Not yet recruiting |
NCT06380452 -
Therapy for Scabies With Two Differently Concentrated Permethrin Creams
|
Phase 3 | |
Completed |
NCT00604084 -
Veron Scabies Education and Eradication Program
|
N/A | |
Completed |
NCT02485717 -
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
|
Phase 3 | |
Completed |
NCT02485704 -
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
|
Phase 3 | |
Recruiting |
NCT05310734 -
PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies
|
Phase 4 | |
Recruiting |
NCT04931680 -
Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
|
||
Completed |
NCT06396507 -
Sulfur vs. Different Regimes of Permethrin for Scabies
|
Phase 3 | |
Completed |
NCT05862701 -
Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies
|
Phase 1 | |
Not yet recruiting |
NCT05500326 -
Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)
|
Phase 2 | |
Recruiting |
NCT04814511 -
Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
|
Phase 3 |